Welcome to the Starpharma investor centre.

Starpharma Holdings Limited is an Australian stock exchange listed biotechnology company with products based on its dendrimer technology platform.

asx.jpg

View All
ASX Announcements

 

Need to update your
shareholder details

 

Download 
Annual Report

View the 
Analyst coverage

 

Have an
Investor query?

 

Register here
for email updates

Latest News & Announcements

Click here for news archive

28 April 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma today released its Appendix 4C – Quarterly Cashflow Report for the period ended 31 March 2017.

Read more

20 April 2017

AstraZeneca DEP® candidate advance triggers milestone to Starpharma

 Starpharma announced the achievement of a key preclinical milestone for its DEP® drug delivery technology in combination with a proprietary oncology molecule from AstraZeneca.

Read more

12 April 2017

Ansell launches VivaGel® condom in Canada

Starpharma is pleased to announce the VivaGel® condom has been launched in Canada by Ansell under the LifeStyles® Dual Protect brand. 

Read more

30 March 2017

VivaGel® BV phase 3 trials for prevention of BV completed

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced completion of its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis (rBV). Starpharma expects topline results of the trials to be available in the second quarter of 2017.

Read more

27 February 2017

Interim Report and Half-Yearly Financial Results

Starpharma released its interim report and financial results for the half-year ended 31 December 2016.

 

Financial Summary

  • Reported loss of $9.0M (Dec 2015: $10.0M)
  • R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
  • Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
  • Receipt of $3.5M R&D tax incentive refund from FY16
Read more

31 January 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2016.

Read more

19 January 2017

Shareholder Update January 2017

In this issue:

›› Enrolment completed for phase 3 program: VivaGel® BV for prevention of recurrence

›› VivaGel® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel® condom approved in Canada; licensed in China and Iran

›› New DEP® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP® cabazitaxel shows no neutropenia

›› DEP® irinotecan internal program shows superior performance

Download: Shareholder Update January 2017  (pdf file, 752kb)


12 January 2017

VivaGel® BV granted QIDP and Fast Track designation by US FDA

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA).

Read more

22 December 2016

Starpharma receives $3.5M R&D tax incentive refund

Starpharma Holdings Ltd today announced it has received the anticipated $3.5M of R&D tax incentive refund related to FY16 expenditures. 

Read more

29 November 2016

AGM Chairman’s address and CEO presentation

Chairman’s address and the CEO’s presentation to the 2016 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).

Read more

28 November 2016

Starpharma signs license for VivaGel® Condom in Iran

Starpharma Holdings Ltd today announced the signing of a License and Supply Agreement with Koushan Pharmed for the sales and marketing rights to the VivaGel® condom in Iran.

Read more

26 October 2016

Starpharma to present at US Drug Delivery Conference

Starpharma will be presenting its DEP™ platform at the 6th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 27-28 October.

Read more
12 ... Next

Reports & Presentations

Click here for financial reports archive

27 February 2017

Interim Report and Half-Yearly Financial Results

Starpharma released its interim report and financial results for the half-year ended 31 December 2016.

 

Financial Summary

  • Reported loss of $9.0M (Dec 2015: $10.0M)
  • R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
  • Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
  • Receipt of $3.5M R&D tax incentive refund from FY16
Read more

31 January 2017

Appendix 4C - Quarterly Cashflow Report

Starpharma released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2016.

Read more

8 November 2016

Starpharma to present at Bio-Europe conference

Starpharma will be presenting at the Bio-Europe® conference held in Cologne, Germany this week. At the conference Starpharma will also be conducting licensing discussions for DEP™ and VivaGel® with pharmaceutical companies.

Read more

26 October 2016

Starpharma to present at US Drug Delivery Conference

Starpharma will be presenting its DEP™ platform at the 6th Annual Partnership Opportunities in Drug Delivery (PODD) conference in Boston, USA, on 27-28 October.

Read more

25 October 2016

Starpharma to present at ASX Spotlight in Asia

Starpharma presents to more than 300 sophisticated and institutional investors as part of the ASX Spotlight Conference in Hong Kong and Singapore.

Read more

30 August 2016

Highlights of FY2016 Presentation: FNN Interview

Starpharma advises a brief audio interview and presentation with Chief Executive Officer Dr Jackie Fairley will be broadcast today by the Finance News Network.

Read more

29 August 2016

Annual Report and full year financial results

Starpharma released its annual report and financial results for the year ended 30 June 2016.

 Financial Results

  • Net cash burn (cash outflows before new capital) $17.5M
  • Cash position at end of the year $46.0M
  • Net proceeds of $32.6M from equity placement and share purchase plan
  • Total revenue and other income $4.6M including the first US$2M DEP™ milestone from AstraZeneca
  • Reported loss $22.7M
  • Receipt of $3.4M R&D tax incentive
Read more

In the Media

Click here for more In the Media

20 April 2017

Starpharma featured on Ticky on Sky Business News

Starpharma CEO Dr Jackie Fairley was interviewed on Ticky on Sky Business News where she discussed the company's VivaGel® portfolio, its DEP® drug delivery technology and its relationship with global pharmaceutical giant AstraZeneca.

 Go to the article (external link)

12 April 2017

Melbourne-based company develops world's first anti-viral condom

 

The ABC notes Starpharma as the Melbourne company developed the world’s first anti-viral condom using its VivaGel® active in the condom lubricant. VivaGel® has been shown to inactivate HIV, herpes, human papillomavirus and the Zika virus in laboratory studies.

 Go to the article (external link)

30 March 2017

VivaGel BV phase 3 trials for prevention of BV completed

Biotech Dispatch reports Starpharma’s recently completed its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis, noting that top-line results are expected in 2Q 2017.

 Go to the article (external link)

13 January 2017

Starpharma VivaGel® BV gets FDA fast track

The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.

 Go to the article (external link)

1 August 2016

The Australian: Starpharma perks up on China condom deal

The Australian’s David Rogers reports that Starpharma has signed “an exclusive license and supply agreement with Shenyang SKY and Land Latex Co for the manufacture and sale of VivaGel condoms to the Government segment of the Chinese condom market”.

Go to the article (external link)

17 May 2016

The Conversation: Antiviral condoms will help protect Australian Olympians from STIs – here’s how

The Conversation noted Dual Protect™ anti-viral condoms, which are coated with Starpharma’s VivaGel®, provide an extra level of protection over regular condoms for Australia athletes when they are at the Olympics in Rio. 

Go to the article (external link)

© Starpharma Holdings Limited 2017